Table 2.

bi- and multi-variate linear regression analysis per CD4⁺CD25^highCD127⁻

			Bivariate			Multivariate
Variable	Category	Coef	95% CI	P-value	Coef	95% CI	P-value
Time	Per each month since Tx	0.16	0.10 to 0.22	<0.001	0.18	0.12 to 0.24	<0.001
CLAD	RAS	−6.60	−11.594 to-1.603	0.01	−5.19	−10.2 to −0.16	0.04
	BOS	−8.14	−11.807 to −4.473	<0.001	−6.51	−10.26 to −2.77	0.001
BOS grade	0p	−2.05	−4.165 to 0.069	0.06
	1	−2.53	−5.122 to 0.068	0.06
	2	−6.49	−9.724 to −3.261	<0.001
	3	−4.90	−8.731 to −1.066	0.01
Lymphocytic population	cd3	0.009	0.008 to 0.01	<0.001
	cd 3 cd4	0.021	0.019 to 0.023	<0.001
	cd 3 cd8	0.01	0.008 to 0.011	<0.001
	cd19	0.05	0.038 to 0.057	<0.001
	cd1 6 cd56	0.01	0.005 to 0.008	<0.001
	cd4cd25high	0.60	0.585 to 0.62	<0.001
Immunosuppressive therapy	Cyclosporine	0.20	−3.598 to 4.007	0.92
	Tacrolimus	−2.71	−5.783 to 0.367	0.08
	Azathioprine	4.65	0.438 to 8.856	0.03	−2.12	−6.73 to 2.48	0.336
	Mycophenolate	0.04	−1.735 to 1.823	0.96
	Rapamycin	−0.75	−3.202 to 1.703	0.55
	Prednisone	−6.32	−15.329 to 2.687	0.17
Azithromycin therapy		−0.74	−2.505 to 1.016	0.41	0.58	−1.28 to 2.43	0.542
Extracorporeal photopheresis		−6.03	−8.259 to −3.804	<0.001	−5.65	−8.05 to −3.25	<0.001
Kidney failure		−1.36	−3.62 to 0.907	0.24

Bold characters mean statistically significant variable

Linear mixed models were fitted, with patient and time since Tx as random effects, and individual predictors and time as fixed effects

CLAD chronic lung allograft dysfunction, RAS restrictive allograft syndrome, BOS bronchiolitis obliterans syndrome